Drug Trial Radar · NCT04553133
PF-07104091 as a Single Agent and in Combination Therapy
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
157
Actual
Start
Sep 16, 2020
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian cancers.
Conditions
- Small Cell Lung Cancer
- Ovarian Cancer
- Breast Cancer
Interventions
PF-07104091 monotherapy dose escalationDrug
PF-07104091 will be administered orally
PF-07104091 + palbociclib + fulvestrantDrug
PF-07104091 will be administered orally in combination with palbociclib and fulvestrant
PF-07104091 + palbociclib + letrozoleDrug
PF-07104091 will be administered orally in combination with palbociclib and letrozole
PF-07104091 monotherapy dose expansion (ovarian)Drug
PF-07104091 will be administered orally
PF-07104091 monotherapy dose expansion (SCLC)Drug
PF-07104091 will be administered orally
PF-07104091 + Fulvestrant (post CDK4/6)Drug
PF-07104091 will be administered orally in combination with fulvestrant
PF-0704091 + Fulvestrant (post CDK4/6)Drug
PF-07104091 + fulvestrant (post 4/6) dose expansion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycleTime frame: 28 days
- To evaluate incidence of treatment emergent adverse events and laboratory abnormalitiesTime frame: From baseline until end of study treatment or study completion (approximately 2 years)
- Evaluate pulse rate that is out of normal range and changes in pulse rate as compared to baselineTime frame: From baseline until end of study treatment or study completion (approximately 2 years)
- Evaluate blood pressure that is out of normal range and changes in blood pressure as compared to baselineTime frame: From baseline until end of study treatment or study completion (approximately 2 years)
- To evaluate heart rate corrected QT interval and changes in corrected QT interval as compared to baselineTime frame: From baseline until end of study treatment or study completion (approximately 2 years)
- To evaluate the preliminary antitumor activity of PF-07104091 as a single agent and in combination with palbociclib and in combination with letrozole or fulvestrant or fulvestrant alone by objective response rate (ORR) in dose expansionTime frame: From baseline through disease progression or study completion (approximately 2 years)
Locations
22 sites in 4 countries. Site status is shown where the registry gives one.
Medical Oncology & Hematology Associates DBA Mission Cancer and Blood
Clive, Iowa
Des Moines Oncology Research Association
Des Moines, Iowa
Medical Oncology & Hematology Associates DBA Mission Cancer and Blood
Des Moines, Iowa
Medical Oncology & Hematology Associates DBA Mission Cancer and Blood
Des Moines, Iowa
Norton Hospital
Louisville, Kentucky
Norton Cancer Institute, St. Matthews Campus
Louisville, Kentucky
Norton Cancer Institute, Audubon
Louisville, Kentucky
Norton Brownsboro Hospital
Louisville, Kentucky
Norton Cancer Institute, Brownsboro Campus
Louisville, Kentucky
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute - Chestnut Hill
Newton, Massachusetts
Memorial Sloan Kettering Monmouth
Middletown, New Jersey
Memorial Sloan Kettering Cancer Center (IDS Pharmacy)
Long Island City, New York
Laura & Isaac Perlmutter Cancer Center - NYU ACC
New York, New York
NYU Langone Medical Center (Tisch Hospital)
New York, New York
White Plains Hospital
White Plains, New York
UVA Breast Care Center
Charlottesville, Virginia
Centro de Investigaciones Medicas y Desarrollo LC
Buenos Aires, Buenos Aires F.D., Argentina
Complex Oncology Center - Plovdiv EOOD
Plovdiv, Bulgaria
Complex Oncology Center - Shumen
Shumen, Bulgaria
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.